Accumulating evidence shows a progressive decline in the efficacy of coronavirus disease
2019 (COVID‐19)(severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]) …

The elicited anti-SARS-CoV-2 immunity is becoming increasingly complex with individuals
receiving a different number of vaccine doses paired with or without recovery from …

The severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) Omicron
variant is spreading rapidly, even in vaccinated individuals, raising concerns about immune …

Two-dose messenger RNA vaccines against the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) are highly effective in preventing symptomatic COVID-19 …

Background The continuous emergence of SARS-CoV-2 variants of concern (VOC) with
immune escape properties, such as Delta (B. 1.617. 2) and Omicron (B. 1.1. 529), questions …

SARS-CoV-2 variants that attenuate antibody neutralization could jeopardize vaccine
efficacy. We recently reported the protective activity of an intranasally administered spike …

SARS-CoV-2 antibody assays are crucial in managing the COVID-19 pandemic. Approved
mRNA COVID-19 vaccines are well known to induce a serum antibody responses against …

Many immunocompromised patients mount suboptimal humoral immunity after SARS-CoV-2
mRNA vaccination. Here, we assessed the single-cell profile of SARS-CoV-2-specific T cells …

Background Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed.
The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines on …

Continuously emerging variants of concern (VOCs) sustain the SARS-CoV-2 pandemic. The
SARS-CoV-2 Omicron/B. 1.1. 529 VOC harbours multiple mutations in the spike protein …